$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

$arwr Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024022215 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$26.16M	$28.05M
YoY Change	-1.98%	11.5%
% of Gross Profit
Research & Development	$152.4M	$101.1M
YoY Change	60.87%	35.04%
% of Gross Profit
Depreciation & Amortization	$4.400M	$4.100M
YoY Change	51.72%	86.36%
% of Gross Profit
Operating Expenses	$176.1M	$126.2M
YoY Change	48.61%	28.63%
Operating Profit	-$176.1M	-$126.2M
YoY Change	71.51%	-362.0%
Interest Expense	$1.404M	$7.244M
YoY Change	-72.78%	43.25%
% of Operating Profit
Other Income/Expense, Net	$2.164M	-$805.0K
YoY Change	-418.24%	64.62%
Pretax Income	-$174.0M	-$127.0M
YoY Change	68.28%	-366.37%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$170.8M	-$125.3M
YoY Change	65.91%	-357.42%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.38	-$1.02
Diluted Earnings Per Share	-$1.38	-$1.02
COMMON SHARES
Basic Shares Outstanding	124.2M shares	123.9M shares
Diluted Shares Outstanding	124.2M shares	123.3M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$436.7M	$523.1M
YoY Change	-3.33%	8.75%
Cash & Equivalents	$69.40M	$127.7M
Short-Term Investments	$367.3M	$395.4M
Other Short-Term Assets	$4.184M	$7.514M
YoY Change	-41.58%	-47.95%
Inventory
Prepaid Expenses	$9.207M	$11.02M
Receivables
Other Receivables
Total Short-Term Assets	$450.1M	$541.7M
YoY Change	-4.28%	-5.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$375.9M	$359.3M
YoY Change	62.47%	93.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.460M	$210.0K
YoY Change	2023.81%	0.0%
Total Long-Term Assets	$433.7M	$413.5M
YoY Change	33.16%	30.65%
TOTAL ASSETS
Total Short-Term Assets	$450.1M	$541.7M
Total Long-Term Assets	$433.7M	$413.5M
Total Assets	$883.8M	$955.2M
YoY Change	11.05%	7.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.55M	$8.521M
YoY Change	237.19%	-10.83%
Accrued Expenses	$47.90M	$37.06M
YoY Change	25.42%	-6.31%
Deferred Revenue	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$96.71M	$65.18M
YoY Change	37.72%	-25.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$448.1M	$394.6M
YoY Change	66876.23%	16.37%
Total Long-Term Liabilities	$448.1M	$394.6M
YoY Change	30.39%	16.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$96.71M	$65.18M
Total Long-Term Liabilities	$448.1M	$394.6M
Total Liabilities	$544.8M	$459.7M
YoY Change	31.63%	7.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.455B	-$1.284B
YoY Change	58.78%	57.88%
Common Stock	$1.787B	$1.769B
YoY Change	39.4%	40.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$330.5M	$483.8M
YoY Change
Total Liabilities & Shareholders Equity	$883.8M	$955.2M
YoY Change	11.05%	7.16%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$170.8M	-$125.3M
YoY Change	65.91%	-357.42%
Depreciation, Depletion And Amortization	$4.400M	$4.100M
YoY Change	51.72%	86.36%
Cash From Operating Activities	-$115.4M	-$92.38M
YoY Change	438.18%	191.68%
INVESTING ACTIVITIES
Capital Expenditures	$14.45M	$34.07M
YoY Change	-69.0%	24.75%
Acquisitions
YoY Change
Other Investing Activities	$21.40M	-$234.9M
YoY Change	-41.69%	2583.83%
Cash From Investing Activities	$6.949M	-$268.9M
YoY Change	-170.16%	645.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	50.39M	430.8M
YoY Change	2691.52%	82741.73%
NET CHANGE
Cash From Operating Activities	-115.4M	-92.38M
Cash From Investing Activities	6.949M	-268.9M
Cash From Financing Activities	50.39M	430.8M
Net Change In Cash	-58.08M	69.46M
YoY Change	96.58%	-203.34%
FREE CASH FLOW
Cash From Operating Activities	-$115.4M	-$92.38M
Capital Expenditures	$14.45M	$34.07M
Free Cash Flow	-$129.9M	-$126.5M
YoY Change	90.84%	114.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107312000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107312000	shares
CY2024Q1	us-gaap	Interest Expense InterestExpense	7244000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	5057000	usd
	us-gaap	Interest Expense InterestExpense	12611000	usd
	us-gaap	Interest Expense InterestExpense	7906000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	418339000	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19390000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	576000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-122000	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-41811000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	396372000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20612000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	520000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-74000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	47676000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	465106000	usd
	us-gaap	Profit Loss ProfitLoss	-262372000	usd
	us-gaap	Profit Loss ProfitLoss	5865000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	37444000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	40002000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8788000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5358000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-896000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	82000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	80000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	12612000	usd
	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	7906000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	68024000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2643000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-20309000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-8402000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6688000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-11000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-27279000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-866000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-99135000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	4417000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1205000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-210217000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-107187000	usd
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124133000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107312000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107312000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44626000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45297000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5285000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10563000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	113632000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	104608000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	3899000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	3003000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	102731000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	66225000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	309982000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	192528000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	208615000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	141994000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-204098000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-116759000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1779000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1096000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	429265000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	arwr	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	0	usd
	arwr	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	250000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	431044000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	251096000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	16729000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	27150000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-196000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110891000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108005000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127704000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134959000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-3014000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7265000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12831000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127700000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2200000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	395400000	usd
	arwr	Increase Decrease In Cash And Investments IncreaseDecreaseInCashAndInvestments	119500000	usd
CY2024Q1	arwr	Development Regulatory And Sales Milestones Payments DevelopmentRegulatoryAndSalesMilestonesPayments	2800000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3300000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	146267000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3551000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	208813000	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	866000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	409223000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	332213000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	49971000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41951000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	359252000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290262000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4100000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7900000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4500000	usd
CY2024Q1	arwr	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	14443000	usd
CY2023Q3	arwr	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	16125000	usd
CY2024Q1	arwr	Accrued Research And Development Co Development Expense Current AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent	13751000	usd
CY2023Q3	arwr	Accrued Research And Development Co Development Expense Current AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent	5895000	usd
CY2024Q1	arwr	Accrued Capital Expenditure Current AccruedCapitalExpenditureCurrent	7265000	usd
CY2023Q3	arwr	Accrued Capital Expenditure Current AccruedCapitalExpenditureCurrent	14044000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1596000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3699000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37055000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39763000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	396249000	usd
CY2024Q1	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent	11000	usd
CY2024Q1	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent	850000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	395410000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	295699000	usd
CY2023Q3	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent	3000	usd
CY2023Q3	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent	2967000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	292735000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	850000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1700000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1700000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1700000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1700000	usd
CY2024Q1	arwr	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	1762000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9412000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124133000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124133000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107312000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107312000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44626000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45297000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5285000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10563000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	113632000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	104608000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	3003000	usd
	us-gaap	Lease Cost LeaseCost	8148000	usd
	us-gaap	Lease Cost LeaseCost	5815000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	400000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	700000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	6997000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15356000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15696000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	14869000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	13511000	usd
CY2024Q1	arwr	Lessee Operating Lease Liability Payments Due Year Five And After Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive	128356000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	194785000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	75868000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	118917000	usd
CY2024Q1	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	0	usd
CY2023Q1	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	8918000	usd
	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	3099000	usd
	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	17929000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	64000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22582000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2046000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1098000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	4016000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2196000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M6D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4553827	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2078693	shares
CY2024Q1	arwr	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding	7169856	shares
	us-gaap	Lease Cost LeaseCost	5815000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	400000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	700000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15356000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15696000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	14869000	usd
CY2024Q1	arwr	Lessee Operating Lease Liability Payments Due Year Five And After Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive	128356000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	194785000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	75868000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	118917000	usd
CY2024Q1	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	0	usd
CY2023Q1	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	8918000	usd
	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	3099000	usd
	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	17929000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	64000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22582000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2046000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1098000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	4016000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2196000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M6D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4553827	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2078693	shares
CY2024Q1	arwr	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding	7169856	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16588000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34273000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40002000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16588000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20613000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34273000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40002000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2263477	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	30437	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	61.11
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	154347	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.53
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2078693	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.04
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26788979	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2054866	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.72
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	26788746	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2263477	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	30437	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	61.11
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	154347	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.53
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2078693	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.04
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26788979	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2054866	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.72
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	26788746	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q3	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	268326000	usd
CY2024Q1	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	12612000	usd
CY2024Q1	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	280938000	usd
CY2023Q3	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	268326000	usd
CY2024Q1	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	12612000	usd
CY2024Q1	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	280938000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-125300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	48675000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-258164000	usd
	us-gaap	Net Income Loss NetIncomeLoss	7350000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123285000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115307000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106394000	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1386000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1499000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123285000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108143000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115307000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.02
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4006000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4350000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4588000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4069000	shares
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-125300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	48675000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-258164000	usd
	us-gaap	Net Income Loss NetIncomeLoss	7350000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123285000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106757000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115307000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106394000	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1386000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1499000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123285000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108143000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115307000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107893000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.02
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4006000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4350000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4588000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4069000	shares
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001628280-24-022215-index-headers.html	Edgar Link	pending
0001628280-24-022215-index.html	Edgar Link	pending
0001628280-24-022215.txt	Edgar Link	pending
0001628280-24-022215-xbrl.zip	Edgar Link	pending
arwr-20240331.htm	Edgar Link	pending
arwr-20240331.xsd	Edgar Link	pending
arwr-2024331xex311.htm	Edgar Link	pending
arwr-2024331xex311001.jpg	Edgar Link	pending
arwr-2024331xex312.htm	Edgar Link	pending
arwr-2024331xex312001.jpg	Edgar Link	pending
arwr-2024331xex321.htm	Edgar Link	pending
arwr-2024331xex321001.jpg	Edgar Link	pending
arwr-2024331xex322.htm	Edgar Link	pending
arwr-2024331xex322001.jpg	Edgar Link	pending
exhibit101-arrowheadindu.htm	Edgar Link	pending
exhibit101-arrowheadindu001.jpg	Edgar Link	pending
exhibit101-arrowheadindu002.jpg	Edgar Link	pending
exhibit101-arrowheadindu003.jpg	Edgar Link	pending
arwr-20240331_cal.xml	Edgar Link	unprocessable
arwr-20240331_def.xml	Edgar Link	unprocessable
arwr-20240331_lab.xml	Edgar Link	unprocessable
arwr-20240331_pre.xml	Edgar Link	unprocessable
exhibit101-arrowheadindu004.jpg	Edgar Link	pending
exhibit101-arrowheadindu005.jpg	Edgar Link	pending
exhibit101-arrowheadindu006.jpg	Edgar Link	pending
exhibit101-arrowheadindu007.jpg	Edgar Link	pending
exhibit101-arrowheadindu008.jpg	Edgar Link	pending
exhibit101-arrowheadindu009.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
arwr-20240331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

2024 Q2 Form 10-Q Financial Statement

#000162828024022215 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARWR ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

2024 Q2 Form 10-Q Financial Statement

#000162828024022215 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr